Novartis Cancer Drug Wins Priority Review

Source: Investopedia

Feb 27, 2017

Novartis announced that its lung cancer drug, Zykadia, has secured priority review status from the U.S. FDA for treating patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase-positive.

Zykadia was first approved in April 2014 as a second-line treatment for patients with metastatic ALK-positive NSCLC who were previously treated with Pfizer's Xalkori.

Novartis has claimed, based on the results of a late-stage study, that its drug is twice as effective as chemotherapy in slowing the growth of non-small cell lung cancer.

Read the Investopedia coverage

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments